ARA-290 (Cibinetide): Human Evidence and Safety

ARA-290—also called cibinetide or pHSBP—is an experimental 11-amino-acid peptide derived from a region of erythropoietin (EPO). It was designed to investigate tissue-protective signaling without EPO’s red-blood-cell-stimulating activity.

The most relevant human evidence is not for general “healing” or inflammation. It comes from short phase 2 studies in people with sarcoidosis-associated small-fiber neuropathy and one small study in people with type 2 diabetes and painful neuropathy. These trials provide an investigational signal, not an established treatment.

The short answer

• ARA-290 is an investigational peptide, not an FDA-approved treatment for neuropathy, pain, diabetes, inflammation, recovery, or longevity.
• Small, short-duration clinical studies reported changes in neuropathy symptom scores and corneal small-nerve-fiber measurements in narrowly selected populations.
• The largest published randomized study enrolled 64 participants. Its primary structural endpoint improved significantly in one tested group, but not in the other two; the placebo-corrected pain result cited for the moderate-to-severe subgroup was not statistically significant.
• There are no large confirmatory phase 3 trials showing durable clinical benefit, no established therapeutic regimen, and limited long-term safety evidence.
• Findings in rodent models of burns, kidney ischemia, autoimmune disease, nerve injury, and aging cannot be presented as human treatment effects.

This guide is educational. Neuropathic pain, numbness, burning, autonomic symptoms, or suspected small-fiber neuropathy warrant clinical evaluation because diabetes, nutritional deficiencies, medication toxicity, autoimmune disease, infection, and genetic conditions can require different management.

ARA-290 and cibinetide refer to the same investigational peptide

ARA-290 was the development name; cibinetide is the adopted nonproprietary name. The peptide was modeled on the solvent-exposed helix B region of EPO, so it is also described as a pyroglutamate helix B surface peptide.

EPO’s established hematologic action involves the erythropoietin receptor and red-blood-cell production. ARA-290 was designed not to trigger that hematopoietic response. Researchers instead proposed signaling through a heteromer involving the EPO receptor and the beta-common receptor CD131, often called the innate repair receptor in this literature.

That mechanism remains a translational hypothesis. Receptor signaling, reductions in inflammatory markers, or inhibition of TRPV1 in cells and animals can explain why a trial was attempted, but they do not establish pain relief or nerve repair in people.

Evidence snapshot

Human trial evidence

Exploratory sarcoidosis pilot

A 2012 double-blind, placebo-controlled pilot enrolled 22 people with sarcoidosis and symptoms of small-fiber neuropathy. After four weeks, the ARA-290 group improved more than placebo on the Small Fiber Neuropathy Screening List. However, average pain and fatigue scores improved in both groups, and the study was explicitly exploratory and too small to establish a treatment effect or characterize uncommon harms.

This distinction matters: a multi-item disease-specific questionnaire can show a signal even when a separate pain scale does not distinguish the intervention from placebo.

Follow-up sarcoidosis studies

A subsequent single-site, blinded, placebo-controlled study reported improvements in neuropathic symptoms, corneal nerve-fiber density, temperature sensitivity, and six-minute walk distance after 28 days. These findings strengthened the case for a larger trial but did not by themselves establish clinical effectiveness.

The registered phase 2b study, NCT02039687, randomized 64 participants with sarcoidosis-associated small-nerve-fiber loss and neuropathic pain across three cibinetide groups and placebo for 28 days. Its primary outcome was corneal nerve fiber area, a structural surrogate rather than pain or everyday function.

The placebo-corrected primary outcome was statistically significant in the middle tested group, but not in the lower or higher groups. A regenerating skin-fiber marker also favored the middle group. Pain improved in all groups. Among participants with moderate-to-severe pain, the reported placebo-corrected pain result for the middle group had a P value of 0.157, which does not meet the conventional 0.05 threshold.

The trial therefore supports further research into small-nerve-fiber structure. It does not prove that ARA-290 reliably relieves pain, reverses neuropathy, or works across causes of small-fiber neuropathy.

Type 2 diabetes and painful neuropathy

A 2015 phase 2 study enrolled 48 people with type 2 diabetes and painful neuropathy. The publication reported improvements in selected neuropathic symptoms, HbA1c, lipids, and corneal nerve-fiber measures. This was a small proof-of-concept study with multiple outcomes and short follow-up. It has not established cibinetide as a glucose-lowering medicine or a treatment for diabetic neuropathy.

The sarcoidosis and diabetes studies also involved overlapping investigators and participation by the drug’s developer. That does not invalidate the results, but independent replication is especially important before interpreting exploratory endpoints as confirmed benefit.

Why corneal nerve fibers are not the same as pain relief

Corneal confocal microscopy can noninvasively quantify nerve-fiber density, length, width, and area. That makes it useful for studying small-fiber loss and possible regeneration. It is still a surrogate measurement.

A surrogate becomes clinically persuasive only when changes reliably predict outcomes patients feel or function through, such as sustained pain reduction, sleep, mobility, autonomic function, or quality of life. In the 64-person trial, correlations between corneal measures and other outcomes were hypothesis-generating; they did not validate corneal nerve fiber area as a substitute for durable clinical benefit.

The non-monotonic result—significance in one tested group but not the lower or higher groups—also deserves caution. It can reflect a real biological relationship, chance, sample variability, or study-design factors. A small phase 2 trial cannot reliably distinguish those explanations.

What the preclinical studies do—and do not—show

ARA-290 has been studied in cells and animal models involving:

• peripheral nerve injury and mechanical allodynia;
• TRPV1 signaling and inflammatory pain;
• burn microcirculation and wound vasculature;
• renal ischemia-reperfusion injury;
• experimental autoimmune neuritis and encephalomyelitis;
• lupus-like disease models;
• diabetic beta-cell function; and
• age-associated cardiac and frailty measurements in mice.

These experiments are useful for mechanism discovery. They do not show that ARA-290 treats burns, kidney disease, Guillain–Barré syndrome, multiple sclerosis, lupus, diabetes, Alzheimer’s disease, or aging in humans. Model-specific changes in cytokines, immune cells, myelin staining, blood vessels, or animal behavior are not clinical outcomes.

The same boundary applies to phrases such as “nerve repair,” “regeneration,” and “anti-inflammatory.” They describe a proposed pathway or measured laboratory outcome unless a controlled human trial demonstrates a meaningful patient benefit.

Safety evidence is still limited

The published human studies were small and generally lasted about four weeks. They can identify common short-term tolerability signals, but they are not large or long enough to rule out uncommon, delayed, immune-mediated, cardiovascular, metabolic, or product-quality risks.

“Nonerythropoietic” means the peptide was designed not to stimulate red-blood-cell production like EPO. It does not mean risk-free, non-immunogenic, or safe for unsupervised use.

Product identity is also part of safety. A clinical trial’s characterized investigational material is not interchangeable with a retail vial using the same name. Peptide sequence, counterion or salt form, aggregation, impurities, sterility, endotoxin, fill accuracy, storage, and route can all affect exposure and risk.

Regulatory and compounding status

FDA’s 2024 503A category document lists Cibinetide (ARA-290) in Category 3: substances nominated for the 503A bulks list without adequate supporting information for FDA to evaluate them. FDA’s current explanation says Category 3 substances are not eligible for the interim enforcement policy applied to Category 1 substances.

This is not the same as FDA approval. A substance record, UNII, adopted name, ClinicalTrials.gov registration, or orphan-drug designation identifies or tracks a development program; none establishes that a marketed product is approved, safe, or effective.

Likewise, “research use only” does not certify identity, purity, or lawful clinical use. The sourcing guide explains the difference between a seller’s claim and a verifiable batch record. The source directory is an availability and documentation index—not a recommendation to purchase or administer ARA-290.

How to evaluate an ARA-290 claim

Use these checks before relying on an article, study, or product page:

1. Match the population. Sarcoidosis-associated neuropathy does not establish benefit for diabetic, chemotherapy-induced, autoimmune, genetic, or idiopathic neuropathy.
2. Separate symptoms from surrogates. Corneal nerve-fiber area, cytokines, and tissue staining are not interchangeable with durable pain relief or daily function.
3. Check the comparator. Improvements from baseline can occur with placebo, regression to the mean, concurrent care, or natural variation.
4. Inspect every tested group. A significant result in one of several groups is weaker when adjacent groups do not show a consistent pattern.
5. Look for adequate follow-up. Four-week exposure cannot establish long-term effectiveness or safety.
6. Check independence and replication. Development-program trials need confirmation by adequately powered independent groups.
7. Match the exact product and route. Evidence does not transfer automatically between formulations or retail sources.
8. Verify regulatory language. Registration, nomination, and orphan designation do not mean approval.

Our research methodology describes how this wiki separates mechanistic, animal, observational, and interventional human evidence.

Related guides

• Peptides studied for healing and recovery
• Peptides studied for brain-related outcomes
• Peptide receptor guide
• Peptide purity testing guide
• Browse research by use case
• Review source availability and batch records

References

1. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Updated 2026.
2. U.S. Food and Drug Administration. 503A Categories Update. September 27, 2024.
3. Heij L, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine. 2012;18:1430–1436.
4. Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine. 2013;19:334–345.
5. Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. 2015;20:658–666.
6. Culver DA, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Investigative Ophthalmology & Visual Science. 2017;58:BIO52–BIO60.
7. U.S. National Library of Medicine. NCT02039687: Study of efficacy of ARA 290 on corneal nerve fiber density and neuropathic symptoms of subjects with sarcoidosis.

Bottom line

ARA-290 has more human research than many peptides marketed for “repair,” but the evidence remains phase 2, short-term, and condition-specific. The strongest signal concerns structural small-nerve-fiber measures in sarcoidosis-associated neuropathy; reliable pain relief, broader disease use, long-term safety, and clinical effectiveness remain unproven.